Immunotoxicity of organophosphorus compounds
Identifieur interne : 003202 ( Main/Exploration ); précédent : 003201; suivant : 003203Immunotoxicity of organophosphorus compounds
Auteurs : Ahmed H. Esa [États-Unis] ; Glenn A. Warr [États-Unis] ; David S. Newcombe [États-Unis]Source :
- Clinical Immunology and Immunopathology [ 0090-1229 ] ; 1988.
English descriptors
- Teeft :
- Antigen presentation, Antigen processing, Assay, Basic science, Commercial mixture, Compound, Counterflow centrifugation elutriation, Diluent control, Dimethyl sulfoxide, Diphenyl phosphate, Environmental xenobiotics, Enzyme activity, Esterase, Esterase activity, Flame retardants, Flow rate, Immune, Immune responses, Immune system, Immunocompetent cells, Immunosuppressive, Immunosuppressive effect, Immunotoxicity, Liquid chromatography, Lymphocyte, Lymphoproliferation, Lymphoproliferative responses, Membrane fluidity, Methyl ester, Microtiter plates, Monocyte, Monocyte accessory functions, Monocyte antigen presentation, Monocyte esterase activity, Monocyte function, Monocyte membrane esterase activity, Mononuclear, Mononuclear cells, Natural logarithm, Noncholinergic mechanisms, Nonstimulated cultures, Organophosphate, Organophosphorous compounds, Organophosphorus, Organophosphorus compounds, Peak response, Pesticide, Present antigen, Proliferative responses, Significant decrease, Significant depression, Statistical significance, Tcpd, Tetanus toxoid, Thiophosphate, Thymidine incorporation, Toxicity, Toxicol, Tppo, Tptp, Trends pharmacol, Triphenyl, Triphenyl phosphate, Triphenyl thiophosphate, Triphenylphosphine oxide, Triplicate determinations.
Abstract
Abstract: Several organophosphorus compounds (OP) used commercially as flame retardants and plasticizers and related chemicals were evaluated for their effects on human in vitro cell-mediated immune responses. At nontoxic concentrations ranging from 0.1 to 20 μM, two of the tested compounds, triphenylphosphine oxide (TPPO) and tetra-o-cresylpiperazinyl diphosphoamidate (TCPD) caused significant suppression of antigenspecific lymphocyte proliferation (P < 0.01). Mitogenesis was less sensitive to OP treatment and was affected only by TCPD. When monocytes and lymphocytes were treated separately with OP, washed, and recombined, it appeared that these OP mediated their suppressive effects by interfering with a monocyte function rather than acting directly on lymphocytes. Further, triphenyl phosphate (TPP), triphenyl thiophosphate (TPTP) as well as TPPO and TCPD were tested for direct inhibition of monocyte antigen presentation, and all four compounds were found to cause significant inhibition at concentrations as low as 1 μM (P < 0.001).
Url:
DOI: 10.1016/0090-1229(88)90093-1
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 002225
- to stream Istex, to step Curation: 002225
- to stream Istex, to step Checkpoint: 001F64
- to stream Main, to step Merge: 003273
- to stream Main, to step Curation: 003202
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Immunotoxicity of organophosphorus compounds</title><author><name sortKey="Esa, Ahmed H" sort="Esa, Ahmed H" uniqKey="Esa A" first="Ahmed H." last="Esa">Ahmed H. Esa</name></author><author><name sortKey="Warr, Glenn A" sort="Warr, Glenn A" uniqKey="Warr G" first="Glenn A." last="Warr">Glenn A. Warr</name></author><author><name sortKey="Newcombe, David S" sort="Newcombe, David S" uniqKey="Newcombe D" first="David S." last="Newcombe">David S. Newcombe</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:D28660F498EDE75D6F8CB79D6C2487872562A211</idno><date when="1988" year="1988">1988</date><idno type="doi">10.1016/0090-1229(88)90093-1</idno><idno type="url">https://api.istex.fr/ark:/67375/6H6-N4C1N8T8-Z/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">002225</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">002225</idno><idno type="wicri:Area/Istex/Curation">002225</idno><idno type="wicri:Area/Istex/Checkpoint">001F64</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001F64</idno><idno type="wicri:doubleKey">0090-1229:1988:Esa A:immunotoxicity:of:organophosphorus</idno><idno type="wicri:Area/Main/Merge">003273</idno><idno type="wicri:Area/Main/Curation">003202</idno><idno type="wicri:Area/Main/Exploration">003202</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">Immunotoxicity of organophosphorus compounds</title><author><name sortKey="Esa, Ahmed H" sort="Esa, Ahmed H" uniqKey="Esa A" first="Ahmed H." last="Esa">Ahmed H. Esa</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>Department of Oncology, The Johns Hopkins Medical Institutions, Baltimore</wicri:cityArea></affiliation><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>Department of Environmental Health Sciences, The Johns Hopkins Medical Institutions, Baltimore</wicri:cityArea></affiliation><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>Department of Medicine, The Johns Hopkins Medical Institutions, Baltimore</wicri:cityArea></affiliation></author><author><name sortKey="Warr, Glenn A" sort="Warr, Glenn A" uniqKey="Warr G" first="Glenn A." last="Warr">Glenn A. Warr</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>Department of Oncology, The Johns Hopkins Medical Institutions, Baltimore</wicri:cityArea></affiliation><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>Department of Environmental Health Sciences, The Johns Hopkins Medical Institutions, Baltimore</wicri:cityArea></affiliation><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>Department of Medicine, The Johns Hopkins Medical Institutions, Baltimore</wicri:cityArea></affiliation><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Connecticut</region></placeName><wicri:cityArea>1Present address: Bristol-Meyers Pharmaceutical Research and Development Division, Wallingford</wicri:cityArea></affiliation></author><author><name sortKey="Newcombe, David S" sort="Newcombe, David S" uniqKey="Newcombe D" first="David S." last="Newcombe">David S. Newcombe</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>Department of Oncology, The Johns Hopkins Medical Institutions, Baltimore</wicri:cityArea></affiliation><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>Department of Environmental Health Sciences, The Johns Hopkins Medical Institutions, Baltimore</wicri:cityArea></affiliation><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>Department of Medicine, The Johns Hopkins Medical Institutions, Baltimore</wicri:cityArea></affiliation></author></analytic><monogr></monogr><series><title level="j">Clinical Immunology and Immunopathology</title><title level="j" type="abbrev">YCLIN</title><idno type="ISSN">0090-1229</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1988">1988</date><biblScope unit="volume">49</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="41">41</biblScope><biblScope unit="page" to="52">52</biblScope></imprint><idno type="ISSN">0090-1229</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0090-1229</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Antigen presentation</term><term>Antigen processing</term><term>Assay</term><term>Basic science</term><term>Commercial mixture</term><term>Compound</term><term>Counterflow centrifugation elutriation</term><term>Diluent control</term><term>Dimethyl sulfoxide</term><term>Diphenyl phosphate</term><term>Environmental xenobiotics</term><term>Enzyme activity</term><term>Esterase</term><term>Esterase activity</term><term>Flame retardants</term><term>Flow rate</term><term>Immune</term><term>Immune responses</term><term>Immune system</term><term>Immunocompetent cells</term><term>Immunosuppressive</term><term>Immunosuppressive effect</term><term>Immunotoxicity</term><term>Liquid chromatography</term><term>Lymphocyte</term><term>Lymphoproliferation</term><term>Lymphoproliferative responses</term><term>Membrane fluidity</term><term>Methyl ester</term><term>Microtiter plates</term><term>Monocyte</term><term>Monocyte accessory functions</term><term>Monocyte antigen presentation</term><term>Monocyte esterase activity</term><term>Monocyte function</term><term>Monocyte membrane esterase activity</term><term>Mononuclear</term><term>Mononuclear cells</term><term>Natural logarithm</term><term>Noncholinergic mechanisms</term><term>Nonstimulated cultures</term><term>Organophosphate</term><term>Organophosphorous compounds</term><term>Organophosphorus</term><term>Organophosphorus compounds</term><term>Peak response</term><term>Pesticide</term><term>Present antigen</term><term>Proliferative responses</term><term>Significant decrease</term><term>Significant depression</term><term>Statistical significance</term><term>Tcpd</term><term>Tetanus toxoid</term><term>Thiophosphate</term><term>Thymidine incorporation</term><term>Toxicity</term><term>Toxicol</term><term>Tppo</term><term>Tptp</term><term>Trends pharmacol</term><term>Triphenyl</term><term>Triphenyl phosphate</term><term>Triphenyl thiophosphate</term><term>Triphenylphosphine oxide</term><term>Triplicate determinations</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: Several organophosphorus compounds (OP) used commercially as flame retardants and plasticizers and related chemicals were evaluated for their effects on human in vitro cell-mediated immune responses. At nontoxic concentrations ranging from 0.1 to 20 μM, two of the tested compounds, triphenylphosphine oxide (TPPO) and tetra-o-cresylpiperazinyl diphosphoamidate (TCPD) caused significant suppression of antigenspecific lymphocyte proliferation (P < 0.01). Mitogenesis was less sensitive to OP treatment and was affected only by TCPD. When monocytes and lymphocytes were treated separately with OP, washed, and recombined, it appeared that these OP mediated their suppressive effects by interfering with a monocyte function rather than acting directly on lymphocytes. Further, triphenyl phosphate (TPP), triphenyl thiophosphate (TPTP) as well as TPPO and TCPD were tested for direct inhibition of monocyte antigen presentation, and all four compounds were found to cause significant inhibition at concentrations as low as 1 μM (P < 0.001).</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Connecticut</li><li>Maryland</li></region></list><tree><country name="États-Unis"><region name="Maryland"><name sortKey="Esa, Ahmed H" sort="Esa, Ahmed H" uniqKey="Esa A" first="Ahmed H." last="Esa">Ahmed H. Esa</name></region><name sortKey="Esa, Ahmed H" sort="Esa, Ahmed H" uniqKey="Esa A" first="Ahmed H." last="Esa">Ahmed H. Esa</name><name sortKey="Esa, Ahmed H" sort="Esa, Ahmed H" uniqKey="Esa A" first="Ahmed H." last="Esa">Ahmed H. Esa</name><name sortKey="Newcombe, David S" sort="Newcombe, David S" uniqKey="Newcombe D" first="David S." last="Newcombe">David S. Newcombe</name><name sortKey="Newcombe, David S" sort="Newcombe, David S" uniqKey="Newcombe D" first="David S." last="Newcombe">David S. Newcombe</name><name sortKey="Newcombe, David S" sort="Newcombe, David S" uniqKey="Newcombe D" first="David S." last="Newcombe">David S. Newcombe</name><name sortKey="Warr, Glenn A" sort="Warr, Glenn A" uniqKey="Warr G" first="Glenn A." last="Warr">Glenn A. Warr</name><name sortKey="Warr, Glenn A" sort="Warr, Glenn A" uniqKey="Warr G" first="Glenn A." last="Warr">Glenn A. Warr</name><name sortKey="Warr, Glenn A" sort="Warr, Glenn A" uniqKey="Warr G" first="Glenn A." last="Warr">Glenn A. Warr</name><name sortKey="Warr, Glenn A" sort="Warr, Glenn A" uniqKey="Warr G" first="Glenn A." last="Warr">Glenn A. Warr</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003202 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003202 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:D28660F498EDE75D6F8CB79D6C2487872562A211
|texte= Immunotoxicity of organophosphorus compounds
}}
| This area was generated with Dilib version V0.6.33. |  |